Regulatory Approval
CuraTeQ Biologics Receives CDSCO Approval for Bevqolva Biosimilar
NSE
auropharma
BSE
524804
Aurobindo Pharma Limited announced that its wholly owned subsidiary, CuraTeQ Biologics, has received CDSCO Marketing Authorisation for Bevqolva®, a Bevacizumab biosimilar indicated for metastatic colorectal cancer treatment in India.
PRICE-SENSITIVE TRIGGER
Event: CDSCO grants marketing authorisation to CuraTeQ Biologics for Bevqolva® biosimilar.
Type: Regulatory Approval
Impact: Positive
Immediate Effect: The approval strengthens Aurobindo Pharma’s biosimilar portfolio and expands its oncology product offerings in the Indian market.
Key Metrics:
- CDSCO granted Marketing Authorisation under Form CT 23
- Approval received for Bevqolva® (Bevacizumab Biosimilar)
- Product approved in:
- 100 mg/4 mL vial
- 400 mg/16 mL vial
- Manufacturing authorised at CuraTeQ’s Hyderabad facility
Highlight:
- The approval marks another important step in Aurobindo Pharma’s expansion into high-value biologics and oncology therapies through CuraTeQ Biologics.
What Happened ?
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma, received CDSCO Marketing Authorisation for Bevqolva®, a biosimilar version of Bevacizumab.
The product is indicated for the treatment of metastatic carcinoma of the colon or rectum. The approval allows manufacturing at the company’s Hyderabad facility and commercial marketing of the product in India.
Key Details
Product Approval Details:
- CDSCO granted approval under Form CT 23
- Product: Bevqolva®
- Molecule: Bevacizumab Biosimilar
- Indication:
- Metastatic carcinoma of colon or rectum
Manufacturing & Commercialisation:
- Product to be manufactured at CuraTeQ’s Hyderabad facility
- Approved vial strengths:
- 100 mg/4 mL
- 400 mg/16 mL
- Strengthens domestic oncology biologics portfolio
Strategic Importance:
- Expands Aurobindo’s biologics and oncology presence
- Enhances capabilities in biosimilar commercialization
- Supports long-term focus on specialty pharmaceutical products
Risk Analysis
Key Risks:
- Competitive pricing pressure in oncology biosimilars
- Regulatory compliance requirements for biologic products
- Market penetration challenges against established therapies
- Commercial execution risks in specialty segments
Worst Case Scenario:
- If market adoption remains slow or competition intensifies significantly, commercial contribution from the biosimilar portfolio may remain limited in the near term.
Risk Level: Medium
Company Commentary
- CuraTeQ confirmed receipt of CDSCO Marketing Authorisation for Bevqolva®
- The approval permits manufacturing and marketing of the biosimilar in India
- Management highlighted the Hyderabad manufacturing facility as the production site
- The company continues strengthening its biosimilar and specialty pharma pipeline
Official Exchange Filing: Aurobindo Pharma Limited